Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

NCT03307980 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

Hemophilia B

Interventions

BIOLOGICAL: PF-06838435 (formerly SPK-9001)

Sponsor

Pfizer